Targeting tumour-infiltrating myeloid cells for prostate cancer therapy


Session type:

Andrea Alimonti1
1Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI)


Tumour-infiltrating myeloid cells are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of T and natural killer (NK) cells and promotes tumour vasculogenesis and progression. Recent evidences demonstrate that the recruitment of myeloid cells in tumours also blocks senescence induced by chemotherapy promoting chemoresistance. I will present novel evidence demonstrating that compounds that interfere with the skewing of tumour-associated macrophages in M2 promote prostate cancer inhibition by enhancing senescence.